Latest Stories
Uncategorized
Smart Ring Maker Oura Files for IPO Seeking Up to $2.2 Billion at a $15.6 Billion Valuation
Oura, the Finnish smart-ring maker, has set terms for a US IPO seeking up to $2.2 billion at a valuation as high as $15.6 billion, after reporting $1.21 billion in revenue for the nine months through June, up 74% from a year earlier.
Uncategorized
Iambic Therapeutics Prices $150 Million Nasdaq IPO to Fund Its Nvidia-Backed AI Drug Pipeline
Iambic Therapeutics priced a $150 million initial public offering at $16 a share on October 14, 2026, becoming one of the first AI-native drug discovery companies to go public, with proceeds earmarked for its early-stage cancer pipeline.
Uncategorized
GSK Expands AI Drug Discovery Deal With Chai Discovery After Its Own Scientists Validate the Models in the Lab
GSK widened its AI drug discovery collaboration with Chai Discovery in October 2026 after its own scientists ran wet-lab tests on Chai's zero-shot protein design models and found binders against every target they tried.
Uncategorized
Andromeda Robotics Brings Its Abi Companion Robot to US Senior Care Facilities After $17 Million Raise
Andromeda Robotics raised $17 million to expand its Abi senior-care companion robot into the US market, part of a growing wave of AI robots aimed at easing loneliness and supporting aging-in-place care.
In-Depth
Uncategorized
Study Warns AI Is Quietly Reshaping How Insurers Decide — and Deny — Health Claims
A Health Affairs study published October 5 examines the consequences of AI-assisted insurance denial appeals, as insurers increasingly automate both claims denials and the appeals process meant to challenge them.
Uncategorized
AI Drug Discovery Deals Top $47 Billion in Just Six Months, Yet No AI-Designed Drug Has Won FDA Approval
AI-based drug discovery licensing deals reached $47.1 billion in the first half of 2026, already surpassing all of 2025's total, even as the industry awaits its first fully FDA-approved AI-discovered drug.
Uncategorized
Zealand Pharma Partners With AI Biotech Generate on Next-Generation Weight-Loss Protein Drugs
Zealand Pharma has linked up with AI protein design company Generate Biomedicines to develop multispecific protein therapies for weight loss, extending the Danish company's pipeline of obesity treatments.
Uncategorized
OpenAI Acquires Orchestra Bio, Folding Drug-Program AI Agents Into Its Rosalind Life Sciences Suite
OpenAI announced on October 20 that it acquired Orchestra Bio, a startup whose AI agents track drug-development timelines for biopharma teams, folding the technology into its Rosalind life sciences suite already used by Moderna and Novo Nordisk.
Uncategorized
Anthropic Buys One-Person Biotech Mithril Medicine, Opens Claude-Run Drug Pipeline With Six Pharma Partners
Anthropic announced on October 27 that it acquired Mithril Medicine, a biotech founded and run by a single scientist, and disclosed six separate pharma collaborations as it moves from selling AI tools to running its own Claude-assisted drug programs.
